Echocardiography and impedance cardiography as determinants of successful slow levosimendan infusion in advanced older heart failure patients  

作　　者：Gaetano Ruocco Guido Pastorini Mauro Feola 

机构地区：[1]Cardiology Unit,Riuniti of Valdichiana Hospital,USL-SUD-EST Toscana,Montepulciano,Siena,Italy [2]Cardiology Unit,Regina Montis Regalis Hospital,ASL-CN1,Mondovì,Cuneo,Italy

出　　处：《Journal of Geriatric Cardiology》2021年第12期1058-1062,共5页老年心脏病学杂志（英文版）

摘　　要：Despite new therapeutic options,patients with heart failure(HF)still progress to advanced stage.In particular,patients who developed a severe left ventricular(LV)systolic and/or diastolic dysfunction with higher degree of NYHA class,recurrent hospitalizations for HF and showing a severe impairment of exercise capacity were defined as“advanced HF”.[1]Levosimendan was recently approved in order to treat patients hospitalized for acute decompensated HF(ADHF)with severe systolic dysfunction.The pharmacolo-gical effects of levosimendan consists of inotropy,vasodilatation and cardioprotection increasing of calcium sensitivity.[2]These effects should be mon-itored with echocardiography.[3]In particular,in ad-vanced HF patients,levosimendan showed positive effects in reducing mortality and three months hos-pitalization;about quality of life and symptoms im-provement,levosimendan showed contrasting ef-fect among the studies on advanced HF patients available.

关 键 词：PATIENTS INFUSION mortality 

分 类 号：R541.6[医药卫生—心血管疾病]